Le Lézard
Classified in: Health, Science and technology
Subjects: PER, SBS

Tracey Mullen Promoted to CEO at Abervis; Garren Hilow Assumes Chief Business Officer Role


BOSTON, July 13, 2020 /PRNewswire/ -- Abveris, a leader in contract research antibody discovery, today announced the promotion of Tracey Mullen from Chief Operating Officer to Chief Executive Officer (CEO), effective July 13, 2020. Current founder and CEO Garren Hilow proactively takes over as Chief Business Officer following Abveris' move out of the startup stage. Hilow initiated the change as part of his focus on growth, which demands new leadership with a strong foundation in science, operations, and drive.

During Mullen's tenure at Abveris, she has been responsible for increasing average monthly revenue by 160%, doubling organic company hires, and co-leading the implementation of the Beacon B cell screening platform. A native of Connecticut, Mullen earned her Bachelor's Degree in Chemical-Biological Engineering from Massachusetts Institute of Technology (MIT), and her Executive Masters of Business Administration from Quantic School of Business and Technology.

"Operating at the forefront of antibody discovery with a strong focus on innovative and transformative new technologies, Abveris has now reached an exciting inflection point and is well positioned for continued growth and success," said Mullen. "I am deeply honored and energized by the opportunity to lead this dynamic organization as we navigate the next generation of antibody therapeutics."

As part of the important leadership transition, Hilow said, "Our business is, and has always been, to make quality biologic drugs. The antibodies we deliver will help cure disease and increase quality of life globally. It is imperative that we continue to push ourselves as an organization to do the best job we possibly can so that we can help make the world a better, healthier place. With Tracey as CEO, Abveris will continue to successfully fulfill that mission."

For additional information on Mullen's new role or Abveris, Inc., please visit: www.abveris.com.

ABOUT ABVERIS:
Abveris is Boston's premier antibody discovery company providing contract research services to the biopharma industry. Abveris applies advanced immunization methods combined with B cell screening and hybridoma-based antibody discovery technologies to provide comprehensive gene-to-antibody discovery services. Abveris is developing the next generation of biologics, cell therapies, vaccines, and diagnostics in partnership with global leaders in biopharma. Additional information about Abveris is available at www.ABVERIS.com.

MEDIA CONTACT:
Sarah Evans
Sevans PR
243229@email4pr.com
224-829-8820

SOURCE Abveris


These press releases may also interest you

at 02:10
SDL plc ("SDL" or the "Group"), the intelligent language and content company, today announces its half year results for the six months ended 30 June 2020. Financial Highlights Unaudited Results 1H20 1H19 Change Change at constant...

at 02:00
cocoa motors. Inc. of Tokyo, Japan started the worldwide sale of a vehicle users can carry with them in a bag, dubbed "WALKCAR," on August 11 on the company's official website. (Logo1: https://kyodonewsprwire.jp/img/202008042803-O1-M5sklPxu)(Logo2:...

at 02:00
Altis Biosystems ("Altis") today announced completion of a seed series investment that was oversubscribed by nearly 50%, raising $3.1 million....

at 01:47
OKEx (www.okex.com), a world-leading cryptocurrency spot and derivatives exchange, released the latest OKB Ecosystem Monthly Report ? July 2020 on Aug. 6. OKB is the global utility token issued by the OK Blockchain Foundation and powers the OKEx...

at 01:15
Fortis Payment Systems, LLC (FortisPay) and Blue Dog Business Services, LLC (BLUEDOG), leading providers of payments technology and merchant services, announced today the merger of the two companies creating a North American integrated commerce...

at 01:00
Firmenich International SA, the world's largest privately-owned Perfume and Taste company, announced its Full Year Results for the 52 weeks ended 30 June 2020.     Financial Highlights Group revenue reached CHF 3,878m, +2.8% growth on a local...



News published on 13 july 2020 at 08:38 and distributed by: